Rigel Pharmaceuticals traded at $1.10 this Friday September 23rd, decreasing $0.06 or 5.17 percent since the previous trading session. Looking back, over the last four weeks, Rigel Pharmaceuticals lost 33.33 percent. Over the last 12 months, its price fell by 70.59 percent. Looking ahead, we forecast Rigel Pharmaceuticals to be priced at 1.07 by the end of this quarter and at 0.97 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
1.10
Daily Change
-5.17%
Yearly
-70.59%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Daiichi Sankyo 4,015.00 -30.00 -0.74% 30.19%
Agenus 2.13 -0.11 -4.91% -63.90%
Applied Genetic Technologies 0.29 -0.01 -2.01% -90.96%
Amgen 226.97 -0.78 -0.34% 6.25%
Anika Therapeutics 23.47 0.01 0.04% -40.76%
Arrowhead Research 30.93 -0.57 -1.81% -52.68%
AstraZeneca 10,016.00 82.00 0.83% 13.24%
Astrazeneca 54.58 -1.73 -3.07% -9.56%
BioMarin Pharmaceutical 84.84 -0.08 -0.09% 7.94%
Bristol-Myers Squibb 70.71 -0.58 -0.81% 17.40%
ChemoCentryx 51.64 -0.14 -0.27% 183.74%
Celldex Therapeutics 27.98 -0.80 -2.78% -49.32%
Halozyme Therapeutics 38.82 0.08 0.21% -3.65%
Heron Therapeutics 3.98 -0.33 -7.66% -68.39%
Immunogen 4.58 -0.12 -2.55% -22.37%
Ionis Pharmaceuticals 43.23 -1.74 -3.87% 19.42%
Karyopharm Therapeutics 4.40 -0.21 -4.56% -29.71%
Ligand Pharmaceuticals 81.12 -0.38 -0.47% -41.72%
Eli Lilly 311.46 0.59 0.19% 34.44%
MacroGenics 3.04 0.03 1.00% -84.60%
Neurocrine Biosciences 103.50 0.16 0.15% 8.96%
Pfizer 44.08 -0.49 -1.10% 0.32%
Ultragenyx Pharmaceutical 41.50 -1.64 -3.80% -56.37%
Regeneron Pharmaceuticals 697.33 9.07 1.32% 9.15%
Rigel Pharmaceuticals 1.10 -0.06 -5.17% -70.59%
Sangamo BioSciences 4.95 -0.09 -1.79% -48.44%
Veracyte 16.58 -0.13 -0.78% -66.08%
Intrexon 2.18 -0.18 -7.63% -58.79%

Indexes Price Day Year
USND 10868 -198.88 -1.80% -27.78%
US2000 1680 -42.72 -2.48% -25.29%

Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. The Company's research focuses on signaling pathways that are critical to disease mechanisms. The Company's product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its clinical program, Fostamatinib is being studied in a Phase III trial for the treatment of warm autoimmune hemolytic anemia (wAIHA). The Company's other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIP1) inhibitor program.